

“DMD 29348”

**A Possible Mechanism for the Decrease in Serum Thyroxine Level by a TCDD-Like PCB Congener, 3,3',4,4',5-Pentachlorobiphenyl in Mice**

Yoshihisa Kato, Koichi Haraguchi, Makiko Kubota, Yoshiki Seto, Takashi Okura, Shin-ichi Ikushiro, Nobuyuki Koga, Shizuo Yamada, and Masakuni Degawa

*Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, Kagawa 769-2193, Japan (Y.K.);*

*Daiichi College of Pharmaceutical Sciences, Fukuoka 815-8511, Japan (K.H.);*

*School of Pharmaceutical Sciences and Global Center of Excellence (COE) Program in the 21<sup>st</sup> Century, University of Shizuoka, Shizuoka 422-8526, Japan (M.K., Y.S., S.Y., M.D.);*

*School of Pharmaceutical Sciences, Teikyo University, Kanagawa 199-0195, Japan (T.O.);*

*Faculty of Engineering, Toyama Prefectural University, Toyama 939-0398, Japan (S.I.); and*

*Faculty of Nutritional Sciences, Nakamura Gakuen University, Fukuoka 814-0198, Japan (N.K.)*

Downloaded from dmd.aspetjournals.org at ASPET Journals on February 4, 2023

“DMD 29348”

Running title: CB126-induced decrease in serum T<sub>4</sub> level

Address correspondence to: Dr. Yoshihisa Kato, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, 1314-1, Shido, Sanuki, Kagawa 769-2193, Japan. Telephone: +81-87-891-5111. Fax: +81-87-894-0181. E-mail: kato@kph.bunri-u.ac.jp

Number of text pages: 27

Number of tables: 4

Number of figures: 10

Number of references: 35

Number of words in the Abstract: 187

Number of words in the Introduction: 426

Number of words in the Discussion: 927

Abbreviations: CB126, 3,3',4,4',5-pentachlorobiphenyl; PCB, polychlorinated biphenyl; T<sub>4</sub>, thyroxine; TTR, transthyretin; TSH, thyroid-stimulating hormone; UGT, UDP-glucuronosyltransferase.

## Abstract

Serum total thyroxine ( $T_4$ ) and free  $T_4$  levels were markedly decreased 7 days after treatment with 3,3',4,4',5-pentachlorobiphenyl (CB126) (2.5 mg/kg, intraperitoneal) in 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD)-sensitive C57BL/6 mice but not in TCDD-resistant DBA/2 mice. At the same time, the level and activity of hepatic  $T_4$ -UDP-glucuronosyltransferase ( $T_4$ -UGT) were significantly increased in C57BL/6 mice but not in DBA/2 mice. Furthermore, the amounts of biliary [ $^{125}$ I] $T_4$  and [ $^{125}$ I] $T_4$ -glucuronide after injection of [ $^{125}$ I] $T_4$  were increased by CB126-pretreatment in C57BL/6 mice, but not in DBA/2 mice. Clearance of [ $^{125}$ I] $T_4$  from serum was also promoted by CB126-pretreatment in C57BL/6 mice, but not in DBA/2 mice. On the other hand, no significant changes in the steady-state volumes of distribution of [ $^{125}$ I] $T_4$  and in the concentration ratio ( $K_p$  value) of the liver to serum by CB126-pretreatment were observed in either strain of mice. Because liver weight was increased by CB126-pretreatment in C57BL/6 mice, but not in DBA/2 mice, hepatic total [ $^{125}$ I] $T_4$  was increased only in C57BL/6 mice. The present findings indicate that CB126-mediated decrease in serum  $T_4$  occurs through the increase in hepatic  $T_4$ -UGT and the enhanced accumulation of hepatic  $T_4$  along with development of liver hypertrophy.

## Introduction

Most polychlorinated biphenyl (PCB) congeners, such as 2,3',4,4',5-pentachlorobiphenyl, 3,3',4,4',5-pentachlorobiphenyl (CB126), and 2,2',4,4',5,5'- and 2,3,3',4,4',5-hexachlorobiphenyls, are known to decrease the levels of serum thyroid hormone and to increase the activities of hepatic drug-metabolizing enzymes in rats and mice (Craft et al., 2002; Desaulniers et al., 1999; Ness et al., 1993; Van Birgelen et al., 1995). As possible mechanism for the PCB-mediated decrease in serum thyroid hormone, the induction of hepatic UDP-glucuronosyltransferases (UGTs), especially UGT1As, responsible for thyroid hormone metabolism and the competition of T<sub>4</sub> and the PCB for binding to transthyretin (TTR) have been proposed (Craft et al., 2002; Brouwer et al., 1998). In addition, hydroxylated PCB show a high binding affinity for serum TTR (Brouwer et al. 1998; Lans et al. 1993; Uacán-Marín et al. 2009). The decrease in serum thyroxine (T<sub>4</sub>) by Aroclor 1254, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), and TCDD-like PCB, CB126, in rats is reported to occur mainly through the induction of the UGT (T<sub>4</sub>-UGT) responsible for T<sub>4</sub> glucuronidation through an aryl hydrocarbon (Ah) receptor-mediated mechanism (Barter and Klaassen, 1994; Schuur et al., 1997; Van Birgelen et al., 1995). However, we have demonstrated that a single and consecutive treatments with Kanechlor-500 (KC500), a commercial PCB mixture, resulted in a significant decrease in serum total T<sub>4</sub> not only in Wistar, but also in Gunn rats (UGT1A-deficient Wistar rats) (Kato et al., 2004, 2007), and further indicated that the KC500-mediated decrease occurs through increased accumulation of T<sub>4</sub> in several tissues, especially the liver, rather than an increase in hepatic T<sub>4</sub>-UGT activity (Kato et al., 2007).

“DMD 29348”

In the present study, therefore, to determine the mechanism for the decrease in serum thyroid hormone by a TCDD-like PCB, we selected CB126 (Fig. 1), because CB126 is a toxic coplanar PCB congener with a toxic equivalency factor (TEF) of 0.1 (Safe, 1994), and generally exists with mixtures of multiple PCB congeners in the environment, and also because it shows anti-estrogenic effects in a human breast cancer cell line (Krishnan and Safe, 1993; Gierthy et al., 1997). We also examined a relationship between the decrease in serum total  $T_4$  and the increase in the hepatic  $T_4$ -UGT. It has been reported that TCDD-induced glucuronidation is observed in rats, but only marginally occurs in mice (Craft et al., 2002). In the present work, therefore, we examined the differences in the CB126-induced alteration of levels of thyroid hormones between TCDD-sensitive C57BL/6 mice and TCDD-insensitive DBA/2 mice. The results strongly suggest that the CB126-mediated decrease in serum total  $T_4$  in mice occurs through the increase in hepatic  $T_4$ -UGT and the enhanced accumulation of  $T_4$  in the liver.

## Materials and Methods

**Chemicals.** Panacete 810 (medium-chain triglycerides) was purchased from Nippon Oils and Fats Co. Ltd. (Tokyo, Japan). The [ $^{125}$ I]T<sub>4</sub>, radiolabelled at the 5'-position of the outer ring, was obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). CB126 were purchased from Cambridge Isotope Laboratories, Inc. (MA, USA). All the other chemicals used herein were obtained commercially in appropriate grades of purity.

**Animal Treatments.** Male C57BL/6 mice (18-31 g) and the DBA/2 mice (18-28 g) were obtained from Japan SLC., Inc. (Shizuoka, Japan). Male C57BL/6 and DBA/2 mice were housed three or four per cage with free access to commercial chow and tap water, maintained on a 12-h dark/light cycle (8:00 AM to 8:00 PM light) in an air-controlled room (temperature,  $24.5 \pm 1^\circ\text{C}$ , humidity,  $55 \pm 5\%$ ), and handled with animal care under the guidelines of the University of Shizuoka (Shizuoka, Japan). Mice received intraperitoneal injection of CB126 (2.5 mg/kg) dissolved in Panacete 810 (5 ml/kg). Control animals were treated with vehicle alone (5 ml/kg).

**A) *In Vivo* Study.** Mice were killed by decapitation 7 days after the administration of CB126. The thyroid gland and liver were removed and weighed. Hepatic microsomes were prepared according to the method of Kato et al. (1995) and stored at  $-85^\circ\text{C}$  until use. Blood was collected from each animal between 10:30 and 11:30 AM. After clotting at room temperature, serum was separated by centrifugation and stored at  $-50^\circ\text{C}$  until use.

**Analysis of serum hormones.** Levels of total T<sub>4</sub>, free T<sub>4</sub>, and thyroid-stimulating hormone (TSH) were measured by radioimmunoassay using Total T<sub>4</sub> and Free T<sub>4</sub> kit (Diagnostic Products Corporation; Los Angeles, CA), and the rTSH [<sup>125</sup>I] Biotrak assay system (GE Healthcare UK, Ltd., Little Chalfont, Buckinghamshire, UK), respectively.

**Hepatic microsomal enzyme assays.** The amount of hepatic microsomal protein was determined by the method of Lowry et al. (1951) with bovine serum albumin as a standard. Microsomal *O*-dealkylase activities of 7-benzyloxy-, 7-ethoxy-, and 7-pentoxo-resorufins were determined by the method of Burke *et al.* (1985). The activity of microsomal UGT toward T<sub>4</sub> (T<sub>4</sub>-UGT activity) was determined by the method of Barter and Klaassen (1992).

**Western blot analysis.** The polyclonal anti-peptide antibodies against the common region of rat UGT1A isoforms and specific antibodies against rat UGT1A1 and UGT2B1, which were established by Ikushiro et al. (1995, 1997), were used. Western blot analyses for microsomal UGT isoforms were performed by the method of Luquita et al. (2001). The bands of mouse Ugt1a1 and Ugt2b1, which correspond to rat UGT1A1 and UGT2B1, respectively, were detected using chemical luminescence (ECL detection kit, GE Healthcare UK, Ltd), and the level of each protein was determined densitometrically with LAS-1000 (Fuji Photo Film. Co., Ltd., Tokyo, Japan).

**B) *Ex Vivo* Study.** At 7 days after treatment with CB126, the mice were anesthetized with saline solution (2 ml/kg) containing sodium pentobarbital (25 mg/ml)

“DMD 29348”

and potassium iodide (1 mg/ml). The femoral artery was cannulated (polyethylene tube SP8, Natsume Inc., Tokyo, Japan) and primed with heparinized saline (33 units/ml), and then animal's body was warmed to 37°C. Fifteen minutes later, the mice were intravenously given 0.1 ml of [<sup>125</sup>I]T<sub>4</sub> (15 μCi /ml) dissolved in saline containing 10 mM NaOH and 1 % normal mouse serum. In addition, since bile was collected within 2.25 hr after pentobarbital administration, pentobarbital-mediated induction of the enzymes responsible for T<sub>4</sub> metabolism is little expected.

**Clearance of [<sup>125</sup>I]T<sub>4</sub> from serum.** Clearance of [<sup>125</sup>I]T<sub>4</sub> from serum was measured according to the method of Oppenheimer et al. (1968). In brief, after the administration of [<sup>125</sup>I]T<sub>4</sub>, a portion (0.08 ml) of blood was sampled from the artery at the indicated times, and serum was prepared and stored at -50°C until use. An aliquot (15 μl) of serum was used for measurement of [<sup>125</sup>I]T<sub>4</sub> level by a γ-counter (COBRA II AUTO-GAMMA 5002; PerkinElmer Life and Analytical Sciences), and the assay was performed in duplicate.

**Biliary excretion of total [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub> glucuronide.** After the administration of [<sup>125</sup>I]T<sub>4</sub>, bile was collected on ice for 2 h at 30 min intervals. Bile volume was determined gravimetrically. The amounts of total [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub> glucuronide in bile were determined by the method of Vansell and Klaassen (2001). In brief, an aliquot (10 μl) of each bile sample was used for determining total [<sup>125</sup>I]T<sub>4</sub> level by a γ-counter (COBRA II AUTO-GAMMA 5002; PerkinElmer Life and Analytical Sciences), and the assay was performed in duplicate. To measure the amount of



“DMD 29348”

[<sup>125</sup>I]T<sub>4</sub> glucuronide in bile, a portion (10 μl) of each bile sample was added 2 volume methanol and stored at -20°C for 1 h to precipitate protein. After the mixture was centrifuged at 12,000 g (4°C) for 10 min, and the resultant supernatant was collected for HPLC analysis. The HPLC analysis was performed using a ChromSpher C18 column (10×0.3 cm) (Chrompack, Inc., Raritan, NJ) in combination with both a ChromSep reverse-phase guard column (10×2 mm) (Chrompack, Inc.) and an Adsorbosphere C18 reverse-phase guard column (7.5×4.6 mm) (Alltech Associates, Inc., Deerfield, IL). A solution of 0.02 mM ammonium acetate (pH 4.0) containing 16-45% acetonitrile was used to elute [<sup>125</sup>I]T<sub>4</sub> glucuronide; 16% of acetonitrile was used as a initial solution for 6 min, and then the elution solution was changed by a linear increase to 27% over 12 min, held for 4 min, followed by a linear increase to 45% over 5 min and held for 11 min. The level of biliary [<sup>125</sup>I]T<sub>4</sub> glucuronide was determined by Radioisotope Detector 171 (Beckman Coulter, Inc. CA USA).

**Analysis of [<sup>125</sup>I]T<sub>4</sub> bound to serum proteins.** The levels of serum [<sup>125</sup>I]T<sub>4</sub>-thyroxine binding globulin (TBG), [<sup>125</sup>I]T<sub>4</sub>-albumin, and [<sup>125</sup>I]T<sub>4</sub>-TTR complexes were determined according to the method of Davis et al. (1970). In brief, serum was diluted in 100 mM phosphate buffer (pH 7.4) containing 1 mM EDTA, 1 mM dithiothreitol, and 30% glycerol, and the diluted serum was subjected to electrophoresis on 4-20% gradient native polyacrylamide gels PAG Mid “Daiichi” 4/20 (Daiichi Pure Chemicals Co., Ltd, Tokyo, Japan). The electrophoresis was performed at 4°C for 11 h at 20 mA in the 0.025 M Tris buffer (pH 8.4) containing 0.192 M glycine. The human albumin and TTR, which were incubated with [<sup>125</sup>I]T<sub>4</sub>, were also

“DMD 29348”

applied on the gel as templates. After the electrophoresis, a gel was dried and radioautographed for 20 h at room temperature using Imaging Plate 2040 (Fuji Photo Film Co., Ltd, Japan). The levels of [ $^{125}\text{I}$ ]T<sub>4</sub>-TBG, [ $^{125}\text{I}$ ]T<sub>4</sub>-albumin, and [ $^{125}\text{I}$ ]T<sub>4</sub>-TTR in serum were determined by counting the corresponding gel fractions identified from Bio Imaging Analyzer (BAS-2000II IP Reader, Fuji Photo Film Co., Ltd, Japan).

**Tissue distribution of [ $^{125}\text{I}$ ]T<sub>4</sub>.** Tissue distribution of [ $^{125}\text{I}$ ]T<sub>4</sub> was performed according to the modified method of Oppenheimer et al. (1968). In brief, at 5 min after administration of [ $^{125}\text{I}$ ]T<sub>4</sub> to CB126-pretreated mice, blood was sampled from abdominal aorta. Then, cerebrum, cerebellum, pituitary gland, thyroid gland, sublingual gland, submandibular gland, thymus, heart, lung, liver, kidney, adreanal gland, spleen, pancreas, testis, prostate gland, seminal vesicle, stomach, duodenum, jejunum, ileum, caecum, brown fat, skeletal muscle, bone marrow skin, spinal cord, and fat were removed and weighed. Radioactivities in serum and the tissues were determined by a  $\gamma$ -counter (COBRA II AUTO-GAMMA 5002; PerkinElmer Life and Analytical Sciences), and amounts of [ $^{125}\text{I}$ ]T<sub>4</sub> in the tissues were shown as ratios to the amount in serum.

**Statistics.** The data obtained were statistically analyzed according to Student's *t* test or Dunnett's test after analysis of variance. In addition, clearance of [ $^{125}\text{I}$ ]T<sub>4</sub> from serum, amount of biliary [ $^{125}\text{I}$ ]T<sub>4</sub> glucuronide, and the binding level of [ $^{125}\text{I}$ ]T<sub>4</sub> bound to serum proteins were statistically analyzed according to Newman-Keuls' test after analysis of variance. The pharmacokinetic parameters of [ $^{125}\text{I}$ ]T<sub>4</sub> were estimated with noncompartmental methods as described previously (Tabata et al., 1999).

## Results

**Serum Hormone Levels.** We carried out the preliminary experiments of the dose-response (CB126: 0.25, 0.5, 1.0, 2.5 and 5.0 mg/kg) and time-course (72, 120, and 168 hr). On the basis of the results, we determined the suitable dose and time (CB126: 2.5 mg/kg, 7 days after the dosing). The effects of CB126 on the levels of serum thyroid hormones were examined in C57BL/6 and DBA/2 mice (Figure 2). Serum total T<sub>4</sub> and free T<sub>4</sub> levels 7 days after the treatment with CB126 were markedly decreased in C57BL/6 mice, but not in DBA/2 mice. On the other hand, no significant increase in the level of serum TSH by CB126-pretreatment was observed in either strain of mice.

**Hepatic Drug-Metabolizing Enzymes.** Effects of CB126 on hepatic microsomal activities of ethoxyresorufin *O*-dealkylase (Cyp1a1/2), benzyloxyresorufin *O*-dealkylase (Cyp2b1/2 and Cyp3a1/2), and pentoxyresorufin *O*-dealkylase (Cyp2b1/2) were examined in C57BL/6 and DBA/2 mice. Treatment of C57BL/6 mice with CB126 resulted in remarkable increases in hepatic microsomal enzyme activities; 73-fold for ethoxyresorufin *O*-dealkylase activity, 7-fold for pentoxyresorufin *O*-dealkylase activity, and 3-fold for benzyloxyresorufin *O*-dealkylase activity. On the other hand, no such CB126-mediated increase was observed in DBA/2 mice (Table 1).

**Hepatic T<sub>4</sub>-UGT.** T<sub>4</sub> glucuronidation is reported to be primarily mediated by hepatic T<sub>4</sub>-UGT, including UGT1A1 and UGT1A6, in the rat liver (Visser, 1996). Therefore, we examined the effects of CB126 on hepatic microsomal T<sub>4</sub>-UGT activity in C57BL/6

and DBA/2 mice. The activity of hepatic T<sub>4</sub>-UGT was significantly increased by CB126 in C57BL/6 mice, but not in DBA/2 mice (Figure 3).

The amounts of the proteins responsible for T<sub>4</sub>-UGTs, including total Ugt1a, Ugt1a1, and Ugt2b1, in mice were determined by Western blot analysis. The amounts of the proteins responsible for the Ugt1a enzymes in the liver were significantly increased by CB126 in C57BL/6 mice but not in DBA/2 mice. The level of hepatic Ugt2b1 was decreased in C57BL/6 mice, whereas the level was not significantly changed in DBA/2 mice by CB126 treatment (Figure 4).

**Biliary Excretion of [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub> Glucuronide.** We examined effects of CB126 on the levels of biliary [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub>-glucuronide in C57BL/6 and DBA/2 mice. The amounts of biliary [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub>-glucuronide after intravenous injection of [<sup>125</sup>I]T<sub>4</sub> were increased by CB126-pretreatment in C57BL/6 mice, but not in DBA/2 mice (Figure 5).

**Serum Proteins Bound to [<sup>125</sup>I]T<sub>4</sub>.** The effects of CB126 on the binding of [<sup>125</sup>I]T<sub>4</sub> to serum proteins, such as TTR, albumin, and TBG, were examined in C57BL/6 and DBA/2 mice (Figures 6 and 7). In CB126-pretreated C57BL/6 mice, the level of serum [<sup>125</sup>I]T<sub>4</sub>-TTR complex slightly increased, while the binding levels of [<sup>125</sup>I]T<sub>4</sub> to serum albumin and TBG slightly decreased. In DBA/2 mice, no such effects of CB126-pretreatment were observed.

**Clearance of [<sup>125</sup>I]T<sub>4</sub> from Serum** After an intravenous administration of [<sup>125</sup>I]T<sub>4</sub> to the CB126-pretreated C57BL/6 and DBA/2 mice, concentrations of [<sup>125</sup>I]T<sub>4</sub> in the

“DMD 29348”

serum were measured at the indicated times (Figure 8). CB126-pretreatment resulted in a clear enhancement of the clearance of [ $^{125}$ I]T<sub>4</sub> from the serum in C57BL/6 mice, but not in DBA/2 mice. The serum [ $^{125}$ I]T<sub>4</sub> level was decreased by about 35% of control level within 5 min, and the decrease remained up to 120 min later. The serum pharmacokinetic parameters of the [ $^{125}$ I]T<sub>4</sub> estimated from these data (Figure 8) were summarized in Table 2. The mean total body clearance (Cl<sub>tb</sub>) of [ $^{125}$ I]T<sub>4</sub> in the CB126-pretreated C57BL/6 mice increased 1.7-fold, as compared with the control mice. On the other hand, no significant change in the steady-state volumes of distribution of [ $^{125}$ I]T<sub>4</sub> by CB126-pretreatment was observed in either strain of mice (Table 2).

**Tissue Distribution of [ $^{125}$ I]T<sub>4</sub>.** Effects of CB126-pretreatment on the tissue-to-serum concentration ratio (K<sub>p</sub> value) and tissue distribution level of [ $^{125}$ I]T<sub>4</sub> were examined in C57BL/6 and DBA/2 mice. The K<sub>p</sub> values in the thyroid gland, liver, and kidney were the greatest in either strain of control mice (Figure 9). K<sub>p</sub> value in the thyroid gland was reduced by CB126-pretreatment in C57BL/6 mice, but not in DBA/2, whereas no such significant changes in the K<sub>p</sub> values of the liver and kidney were observed in either strain of mice (Figure 9).

In the control C57BL/6 and DBA/2 mice, accumulation of [ $^{125}$ I]T<sub>4</sub> was the highest in the liver among the tissues examined (Figure 10). In C57BL/6 mice, pretreatment with CB126 resulted in increase in hepatic total [ $^{125}$ I]T<sub>4</sub>, and the accumulated level in the liver was to more than 49% of the [ $^{125}$ I]T<sub>4</sub> dosed (Figure 10), whereas no significant change in liver accumulation (per g liver) of [ $^{125}$ I]T<sub>4</sub> by CB126-pretreatment was observed (Table 3). In DBA/2 mice, no significant change in accumulation of [ $^{125}$ I]T<sub>4</sub> in the liver by CB126 occurred. In addition, treatment of C57BL/6 mice with CB126

“DMD 29348”

resulted in significant increases in weights of liver and thyroid gland and in significant decreases in weights of thymus and caecum. In DBA/2 mice, the CB126 treatment resulted in slight increases in weights of liver, kidney, seminal vesicle, stomach, jejunum, ileum and caecum and in a significant decrease in weight of thymus (Table 4).

## Discussion

In the present study, treatment with CB126 (a single intraperitoneal administration at a dose of 2.5 mg/kg) resulted in a significant decrease in serum total T<sub>4</sub> and free T<sub>4</sub> in C57BL/6 mice, but not in DBA/2 mice. The strain-difference in CB126-mediated decrease in the serum T<sub>4</sub> level was closely correlated with those in the increases in the activities of hepatic drug metabolizing enzymes, including T<sub>4</sub>-UGT and in accumulation of T<sub>4</sub> in the liver.

As a possible explanation for the TCDD-like PCB-induced decrease in serum thyroid hormones, hepatic T<sub>4</sub>-UGT-dependent mechanism was considered, because T<sub>4</sub>-UGT inducers, such as TCDD and CB126, have strong activities for decreasing serum total thyroid hormones in rats (Schuur et al., 1997; Van Birgelen et al., 1995). Furthermore, we confirmed that the activity of hepatic T<sub>4</sub>-UGT (Ugt1a and Ugt1a1) was significantly increased by CB126-treatment in C57BL/6 mice, but not in DBA/2 mice, and further found that the amounts of biliary [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub>-glucuronide after intravenous injection of [<sup>125</sup>I]T<sub>4</sub> were increased by CB126-pretreatment in C57BL/6 mice, but not in DBA/2 mice, suggesting that the induction of hepatic T<sub>4</sub> removal occurs more likely at the level of basolateral transport of T<sub>4</sub>. The previous reports and the present findings strongly suggest that induction of hepatic T<sub>4</sub>-UGT is one of factors that mediate the decrease in serum T<sub>4</sub> level by CB126. In addition, our present result of the CB126-mediated decrease in the level of Ugt2b1 in C57BL/6 mice was identified with the previous results (Buckley and Klaassen, 2009).

However, among the rats and mice treated with a TCDD-like PCB, the difference in magnitude of decrease in serum total T<sub>4</sub> dose not correlate with that of hepatic T<sub>4</sub>-UGT

“DMD 29348”

activity (Craft et al., 2002, Hood et al., 2003). Recently, we have demonstrated a hepatic T<sub>4</sub>-UGT-independent pathway for PCB-mediated decrease in serum total thyroid hormones using Wistar and Gunn (T<sub>4</sub>-UGT-deficient) rats and further indicated that an increase in the accumulation of T<sub>4</sub> in livers of PCB-treated rats is partially responsible for the decrease in serum total thyroid hormones including T<sub>4</sub> (Kato et al., 2007). In addition, serum TSH and hepatic type-I iodothyronine deiodinase, which are important the factors regulating serum thyroid hormones, are not induced by PCB in rats (Hallgren et al., 2001; Hood et al., 1999; Liu et al., 1995, Kato et al., 2004). Likewise, CB126-treatment did not increase serum TSH in both C57BL/6 and DBA/2 mice. Furthermore, enhanced accumulation of T<sub>4</sub> in the tissues, especially liver, was observed in CB126-pretreated C57BL/6 mice, but not in CB126-pretreated DBA/2 mice, strongly suggesting that the enhancement of overall amount of T<sub>4</sub> in liver is one of the factors which mediate PCB-induced decrease in serum total thyroid hormones in mice.

As a possible mechanism for CB126-mediated enhancement of T<sub>4</sub> accumulation in liver, a TTR-associated pathway might be considered, because PCB and its hydroxylated metabolites act as competitors for T<sub>4</sub> for binding to TTR, and because a decrease in T<sub>4</sub>-TTR complex formation results in an increase in serum free T<sub>4</sub> and then in uptake of T<sub>4</sub> into the liver (Brouwer et al., 1998; Lans et al., 1993; Meerts et al., 2002; Kato et al., 2004). However, the present study concerning the fate of serum T<sub>4</sub> using [<sup>125</sup>I]T<sub>4</sub> indicates that only a slight increase in serum [<sup>125</sup>I]T<sub>4</sub>-TTR complex and only a slight decrease in binding of level of [<sup>125</sup>I]T<sub>4</sub> to serum albumin and TBG in CB126-pretreated C57BL/6 mice. In addition, although some hydroxylated metabolites of PCBs are known to show higher capacity for binding to TTR (Brouwer et al., 1998; Lans et al., 1993; Ucán-Marín et al., 2009), the hydroxylated metabolites of



“DMD 29348”

CB126 were minimally detected in the serum and liver in CB126-pretreated C57BL/6 mice (data not shown), as described previously by Koga et al (1990). The previous reports and the present findings indicate that a TTR-associated pathway is not considered a primary mechanism for CB126-mediated decrease in serum total T<sub>4</sub>. However, it was found that CB126-induced liver hypertrophy occurred in C57BL/6 mice but not in DBA/2 mice, and only a small change in the concentration of T<sub>4</sub> (per g tissue) livers of both C57BL/6 and DBA/2 mice. Therefore, the CB126-induced increase in accumulation of hepatic T<sub>4</sub> in C57BL/6 mice is thought to occur mainly through development of liver hypertrophy.

However, the increases in tissue weights were not necessarily correlated with those in accumulation of [<sup>125</sup>I]T<sub>4</sub> in the tissues of the CB126-pretreated mice. For example, no CB126-induced accumulation of [<sup>125</sup>I]T<sub>4</sub> was observed in the thyroid gland in C57BL/6 mice. Although an exact mechanism for a liver-selective accumulation of [<sup>125</sup>I]T<sub>4</sub> by CB126 remains unclear, the liver-selective apparatus for T<sub>4</sub>-transportation might exist. In addition, CB126-induced development of liver hypertrophy was herein found to occur in C57BL/6 mice, but not DBA/2 mice, confirming that the development of liver hypertrophy occurs in an Ah receptor-dependent pathway (Yoshizawa et al., 2007). Although it has been reported that CB126-induced development of liver hypertrophy occurs in the rat liver (Yoshimura et al., 1979), there is no report, except with our present paper, concerning the CB126-induced change in the level of T<sub>4</sub> in the liver. Therefore, it is unclear whether CB126-enhanced accumulation of [<sup>125</sup>I]T<sub>4</sub> in the liver occurs specifically in mice. Furthermore, in DBA/2 mice, CB126-pretreatment resulted in increases in K<sub>p</sub> values of [<sup>125</sup>I]T<sub>4</sub> in the thymus and fat, while it did decrease in the value in the heart. A mechanism for the tissue-difference in the CB126-mediated

“DMD 29348”

changes in the  $K_p$  value remains unclear.

In conclusion, we demonstrate that CB126-mediated decrease serum  $T_4$  in mice occurs not only through increases in hepatic drug-metabolizing enzymes, especially  $T_4$ -UGT, but also through development of liver hypertrophy.

## References

- Barter RA and Klaassen CD (1992) Rat liver microsomal UDP-glucuronosyltransferase activity toward thyroxine: Characterization, induction, and form specificity. *Toxicol Appl Pharmacol* **115**:261-267.
- Barter RA and Klaassen CD (1994) Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. *Toxicol Appl Pharmacol* **128**:9-17.
- Brouwer A, Morse DC, Lans MC, Schuur AG, Murk AJ, Klasson-Wehler E, Bergman Å, and Visser TJ (1998) Interactions of persistent environmental organohalogenes with the thyroid hormone system: Mechanisms and possible consequences for animal and human health. *Toxicol Ind Health* **14**:59-84.
- Buckley DB and Klaassen CD (2009) Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. *Drug Metab Dispos* **37**:847-856.
- Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, and Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. *Biochem Pharmacol* **34**:3337-3345.
- Craft ES, DeVito MJ, and Crofton KM (2002) Comparative responsiveness of hypothyroxinemia and hepatic enzyme induction in Long-Evans rats versus C57BL/6J mice exposed to TCDD-like and phenobarbital-like polychlorinated

- biphenyl congeners. *Toxicol Sci* **68**:372-380.
- Davis PJ, Spaulding SW, and Gregerman RI (1970) The three thyroxine-binding proteins in rat serum: Binding capacities and effects of binding inhibitors. *Endocrinology* **87**:978-986.
- Desaulniers D, Leingartner K, Wade M, Fintelman E, Yagminas A, and Foster WG (1999) Effects of acute exposure to PCBs 126 and 153 on anterior pituitary and thyroid hormones and FSH isoforms in adult Sprague Dawley male rats. *Toxicol Sci* **47**:158-169.
- Gierthy JF, Arcaro KF, and Floyd M (1997) Assessment of PCB estrogenicity in a human breast cancer cell line. *Chemosphere* **34**:1495-1505.
- Hallgren S, Sinjari T, Håkansson H, and Darnerud PO (2001) Effects of polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) on thyroid hormone and vitamin A levels in rats and mice. *Arch Toxicol* **75**:200-208.
- Hood A, Hashmi R, and Klaassen CD (1999) Effects of microsomal enzyme inducers on thyroid-follicular cell proliferation, hyperplasia, and hypertrophy. *Toxicol Appl Pharmacol* **160**:163-170.
- Hood A, Allen ML, Liu Y, Liu J, and Klaassen CD (2003) Induction of T<sub>4</sub> UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers. *Toxicol Appl Pharmacol* **188**:6-13.
- Ikushiro S, Emi Y, and Iyanagi T (1995) Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptide antibodies. *Arch Biochem Biophys* **324**:267-272.
- Ikushiro S, Emi Y, and Iyanagi T (1997) Protein-protein interactions between

“DMD 29348”

- UDP-glucuronosyltransferase isozymes in rat hepatic microsomes. *Biochemistry* **36**:7154-7161.
- Kato Y, Haraguchi K, Kawashima M, Yamada S, Masuda Y, and Kimura R (1995) Induction of hepatic microsomal drug-metabolizing enzymes by methylsulphonyl metabolites of polychlorinated biphenyl congeners in rats. *Chem-Biol Interact* **95**:257-268.
- Kato Y, Ikushiro S, Haraguchi K, Yamazaki T, Ito Y, Suzuki H, Kimura R, Yamada S, Inoue T, and Degawa M (2004) A possible mechanism for decrease in serum thyroxine level by polychlorinated biphenyls in Wistar and Gunn rats. *Toxicol Sci* **81**:309-315.
- Kato Y, Ikushiro S, Takiguchi R, Haraguchi K, Koga N, Uchida S, Sakaki T, Yamada S, Kanno J, and Degawa M (2007) A novel mechanism for polychlorinated biphenyl-induced decrease in serum thyroxine level in rats. *Drug Metab Dispos* **35**:1949-1955.
- Koga N, Beppu M, and Yoshimura H (1990) Metabolism *in vivo* of 3,4,5,3',4'-pentachlorobiphenyl and toxicological assessment of the metabolite in rats. *J Pharmacobiodyn* **13**:497-506.
- Krishnan V and Safe S (1993) Polychlorinated biphenyls (PCBs), dibenzo-*p*-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: Quantitative structure-activity relationships. *Toxicol Appl Pharmacol* **120**:55-61.
- Lans MC, Klasson-Wehler E, Willemsen M, Meussen E, Safe S, and Brouwer A (1993) Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-*p*-dioxins and -dibenzofurans with human transthyretin. *Chem-Biol*

*Interact* **88**:7-21.

Liu J, Liu Y, Barter RA, and Klaassen CD (1995) Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: A dose-response study. *J Pharmacol Exp Ther* **273**:977-985.

Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**:265-275.

Luquita MG, Catania VA, Pozzi EJS, Veggi LM, Hoffman T, Pellegrino JM, Ikushiro S, Emi Y, Iyanagi T, Vore M, and Mottino AD (2001) Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. *J Pharmacol Exp Ther* **298**:49-56.

Meerts IATM, Assink Y, Cenijn PH, van den Berg JHJ, Weijers BM, Bergman Å, Koeman JH, and Brouwer A (2002) Placental transfer of a hydroxylated polychlorinated biphenyl and effects on fetal and maternal thyroid hormone homeostasis in the rat. *Toxicol Sci* **68**:361-371.

Ness DK, Schantz SL, Moshtaghian J, and Hansen LG (1993) Effects of perinatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat. *Toxicol Lett* **68**:311-323.

Oppenheimer JH, Bernstein G, and Surks MI (1968) Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital. *J Clin Invest* **47**:1399-1406.

Safe SH (1994) Polychlorinated biphenyls (PCBs): Environmental impact, biochemical and toxic responses, and implications for risk assessment. *Crit Rev Toxicol* **24**:87-149.

Schuur AG, Boekhorst FM, Brouwer A, and Visser TJ (1997) Extrathyroidal effects of

“DMD 29348”

- 2,3,7,8-tetrachlorodibenzo-*p*-dioxin on thyroid hormone turnover in male Sprague-Dawley rats. *Endocrinology* **138**:3727-3734.
- Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, and Hata T (1999) Moment analysis program available on Microsoft Excel®. *Xenobio Metabol Dispos* **14**:286-293.
- Ucán-Marín F, Arukwe A, Mortensen A, Gabrielsen GW, Fox GA, and Letcher RJ (2009) Recombinant transthyretin purification and competitive binding with organohalogen compounds in two gull species (*Larus argentatus* and *Larus hyperboreus*). *Toxicol Sci* **107**:440-450.
- Van Birgelen APJM, Smit EA, Kampen IM, Groeneveld CN, Fase KM, van der Kolk J, Poiger H, van den Berg M, Koeman JH, and Brouwer A (1995) Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: Use in risk assessment. *Eur J Pharmacol* **293**:77-85.
- Visser TJ (1996) Pathways of thyroid hormone metabolism. *Acta Med Austriaca* **23**:10-16.
- Vansell NR and Klaassen CD (2001) Increased biliary excretion of thyroxine by microsomal enzyme inducers. *Toxicol Appl Pharmacol* **176**:187-194.
- Yoshimura H, Yoshihara S, Ozawa N, and Miki M (1979) Possible correlation between induction modes of hepatic enzymes by PCBs and their toxicity in rats. *Ann N Y Acad Sci* **31**: 179-192.
- Yoshizawa K, Heatherly A, Malarkey DE, Walker NJ, Nyska A (2007) A critical comparison of murine pathology and epidemiological data of TCDD, PCB126, and PeCDF. *Toxicol Pathol* **35**: 865-79.

“DMD 29348”

### **Footnotes**

This work was supported in part by the Grant-in-Aid for Scientific Research (C) (no. 20510070, Y.K.) and for Scientific Research (B) (no. 19310042, K.H., Y.K.) from Japan Society for the Promotion of Science.



## Legends for figures

Fig. 1. Chemical structure of 3,3',4,4',5-pentachlorobiphenyl.

Fig. 2. Effects of CB126 on the levels of serum total T<sub>4</sub>, free T<sub>4</sub>, and TSH. Animals were killed 7 days after the administration of CB126 (2.5 mg/kg), and levels of serum thyroid hormones were measured, as described in *Materials and Methods*. Each column represents the mean ± S.E. (vertical bars) for four to seven animals. \**P*<0.05, significantly different from each control.

Fig. 3. Effect of CB126 on the activity of hepatic microsomal T<sub>4</sub>-UDPGT. Hepatic microsomes from individual animals were used for T<sub>4</sub>-UDPGT enzyme assay, as described in *Materials and Methods*. Each column represents the mean ± S.E. (vertical bars) for four to seven animals. \**P*<0.05, significantly different from each control.

Fig. 4. Representative Western blot patterns for hepatic microsomal Ugt isoforms in CB126-treated mice. Hepatic microsomes from individual animals were used for Western blot analysis, as described in *Materials and Methods*.

Fig. 5. Effect of CB126 on amounts of the biliary total [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub>-glucuronide. The levels of total [<sup>125</sup>I]T<sub>4</sub> and [<sup>125</sup>I]T<sub>4</sub>-glucuronide excreted were measured in the bile collected at 30 min intervals after the i.v. administration of [<sup>125</sup>I]T<sub>4</sub>.

“DMD 29348”

Each point represents the mean  $\pm$  S.E. (vertical bars) for five to eight mice. \* $P$ <0.05, significantly different from each control. —○—, control; —■—, CB126.

Fig. 6. Effects of CB126 on the binding of [ $^{125}$ I]T<sub>4</sub> to serum proteins in C57BL/6 mice. The amounts of [ $^{125}$ I]T<sub>4</sub> bound to the serum proteins 5 min after [ $^{125}$ I]T<sub>4</sub>-administration were assessed by the method as described in *Materials and Methods*. Each column represents the mean  $\pm$  S.E. (vertical bars) for five to six animals. \* $P$ <0.05, significantly different from each control.

Fig. 7. Effects of CB126 on the binding of [ $^{125}$ I]T<sub>4</sub> to serum proteins in DBA/2 mice. Experimental protocols were the same as those described in the legend of Fig. 6. Each column represents the mean  $\pm$  S.E. (vertical bars) for four to five animals.

Fig. 8. Effects of CB126 on the clearance of [ $^{125}$ I]T<sub>4</sub> from serum. The amount of serum [ $^{125}$ I]T<sub>4</sub> was measured at the indicated times after the i.v. administration of [ $^{125}$ I]T<sub>4</sub>. Each point represents the mean  $\pm$  S.E. (vertical bars) for five to eight mice. \* $P$ <0.05, significantly different from each control. —○—, control; —■—, CB126.

Fig. 9. Tissue-to-serum concentration ratio (K<sub>p</sub> value) of [ $^{125}$ I]T<sub>4</sub> in various tissues after administration of [ $^{125}$ I]T<sub>4</sub> to CB126-pretreated mice. CB126 (2.5 mg/kg) was given to mice, and 168 hr after the CB126-treatment, [ $^{125}$ I]T<sub>4</sub> were further administered to the mice. At 5 min after the [ $^{125}$ I]T<sub>4</sub>-administration, the radioactivity in each tissue was measured, as described in *Materials and Methods*. Each column represents the

“DMD 29348”



mean  $\pm$  S.E. (vertical bars) for five to seven animals. \* $P$ <0.05, significantly different from each control. , control; , CB126.



Fig. 10. Tissue distribution of [ $^{125}$ I]T<sub>4</sub> after the administration of [ $^{125}$ I]T<sub>4</sub> to CB126-pretreated mice. Experimental protocols were the same as those described in the legend of Fig. 9. Each column represents the mean  $\pm$  S.E. (vertical bars) for five to seven animals. \* $P$ <0.05, significantly different from each control. , control; , CB126.

Table 1. Effects of CB126 on the activity of hepatic microsomal alkoxyresorufin *O*-dealkylases in C57BL/6 and DBA/2 mice

<i>O</i> -Dealkylase of alkoxyresolfin	C57BL/6		DBA/2	
	Control	CB126	Control	CB126
7-Ethoxy-	0.20 ± 0.02	14.29 ± 0.56*	0.18 ± 0.01	0.21 ± 0.01*
7-Benzyloxy-	0.12 ± 0.02	0.38 ± 0.01*	0.07 ± 0.01	0.10 ± 0.01
7-Pentoxy-	0.02 ± 0.002	0.15 ± 0.01*	0.02 ± 0.001	0.03 ± 0.003*

Animals were killed 7 days after the administration of CB126 (2.5 mg/kg). The activities of alkoxyresolfin *O*-dealkylase are represented as nmol of the resolfin formed /mg protein/min. Data represent the mean ± S.E. for four to five mice. \* $P < 0.05$ , significantly different from each control.

“DMD 29348”

Table 2. Pharmacokinetic parameters for [<sup>125</sup>I]T<sub>4</sub> after the administration of [<sup>125</sup>I]T<sub>4</sub> to the CB126-pretreated mice

	C57BL/6		DBA/2	
	Non (control)	CB126	Non (control)	CB126
Mean total body clearance (ml/min)	0.015 ± 0.001	0.025 ± 0.002*	0.012 ± 0.0003	0.012 ± 0.001
Distribution volume (ml)	2.90 ± 0.17	3.06 ± 0.12	2.50 ± 0.08	2.72 ± 0.06

The data shown was calculated from the data in Fig. 8. The values shown are expressed as the mean ± S.E. for five to eight mice. \**P*<0.05, significantly different from each control.

Table 3. Accumulation of [<sup>125</sup>I]T<sub>4</sub> in the CB126-pretreated mouse livers

	C57BL/6		DBA/2	
	Control	CB126	Control	CB126
[ <sup>125</sup> I]T <sub>4</sub>	27.13 ± 1.06	24.16 ± 0.67	25.25 ± 1.02	23.59 ± 0.62

[<sup>125</sup>I]T<sub>4</sub> level is represented as % dose per g liver. The radioactivity in the liver was measured at 5 min after the [<sup>125</sup>I]T<sub>4</sub>-administration. Data represent the mean ± S.E. for five to seven mice.


“DMD 29348”

Table 4. Changes in the body and tissue weights after the administration of CB126 to C57BL/6 and DBA/2 mice

Body and tissues	C57BL/6		DBA/2	
	Control	CB126	Control	CB126
Body	25.9 ± 0.21	25.4 ± 0.20	25.2 ± 0.30	25.8 ± 0.53
Cerebrum	0.322 ± 0.004	0.311 ± 0.004	0.275 ± 0.005	0.268 ± 0.002
Cerebellum	0.094 ± 0.008	0.107 ± 0.0003	0.114 ± 0.002	0.118 ± 0.004
Pituitary gland	0.0011 ± 0.0001	0.0013 ± 0.0001	0.0013 ± 0.0002	0.0014 ± 0.0001
Thyroid gland	0.0019 ± 0.0001	0.0023 ± 0.0001*	0.0022 ± 0.0001	0.0023 ± 0.0002
Sublingual gland	0.048 ± 0.003	0.047 ± 0.002	0.054 ± 0.002	0.058 ± 0.003
Submandibular gland	0.092 ± 0.006	0.091 ± 0.003	0.094 ± 0.002	0.098 ± 0.002
Thymus	0.020 ± 0.002	0.008 ± 0.0007*	0.033 ± 0.001	0.029 ± 0.001*
Heart	0.112 ± 0.003	0.107 ± 0.002	0.117 ± 0.002	0.119 ± 0.003
Lung	0.129 ± 0.003	0.132 ± 0.002	0.121 ± 0.0030	0.123 ± 0.0019
Liver	1.149 ± 0.073	2.029 ± 0.030*	1.234 ± 0.034	1.366 ± 0.041*
Kidney	0.319 ± 0.008	0.330 ± 0.004	0.361 ± 0.011	0.407 ± 0.014*
Adrenal gland	0.0028 ± 0.0002	0.0027 ± 0.0003	0.0030 ± 0.0001	0.0030 ± 0.0002
Spleen	0.071 ± 0.005	0.063 ± 0.002	0.082 ± 0.001	0.090 ± 0.006
Testis	0.194 ± 0.004	0.189 ± 0.003	0.224 ± 0.007	0.233 ± 0.005
Prostate gland	0.040 ± 0.002	0.044 ± 0.003	0.046 ± 0.003	0.057 ± 0.004
Seminal vesicle	0.165 ± 0.010	0.171 ± 0.013	0.160 ± 0.010	0.194 ± 0.004*
Stomach	0.257 ± 0.026	0.262 ± 0.020	0.299 ± 0.023	0.438 ± 0.039*
Duodenum	0.186 ± 0.006	0.180 ± 0.007	0.147 ± 0.001	0.154 ± 0.009
Jejunum	0.390 ± 0.006	0.399 ± 0.023	0.401 ± 0.018	0.453 ± 0.009*
Ileum	0.511 ± 0.047	0.457 ± 0.024	0.488 ± 0.019	0.641 ± 0.050*
Caecum	0.477 ± 0.042	0.294 ± 0.009*	0.290 ± 0.004	0.390 ± 0.027*

Animals were killed 7 days after the administration of CB126 (2.5 mg/kg). Data represent the mean ± S.E. for five to seven mice. \* $P < 0.05$ , significantly different from each control.

Fig. 1



3,3',4,4',5-pentachlorobiphenyl  
(CB126)



Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9






Fig. 10

